.jpg)
IN VITRO METHOD FOR THE DIAGNOSIS OR PROGNOSIS OF NEURODEGENERATIVE DISORDERS
US2022113320
This invention focuses on an in vitro method for the diagnosis or prognosis of neurodegenerative disorders. The method comprises measuring the level of expression or the concentration level of at least a lipoprotein receptor-related protein (LRP) or a fragment thereof.
New method to improve the diagnosis/prognosis of several neurodegenerative diseases: major depression, multiple sclerosis or Alzheimer.
The invention includes an in vitro method for the diagnosis or prognosis of neurodegenerative disorders in a subject, including major depression, multiple sclerosis or Alzheimer disease. The method comprises the measurement of the level of expression, or the concentration level, where if a deviation or variation of the level of the protein occurs, it is identified as compared to the level measured in healthy controls. <p>
FIG. 1, Expression of LRP2 and LRP1 in the human choroid plexus, left, and LRP2 in neurons, right. Immunofluorescence with confocal microscopy in human tissues choroid plexus, culture of neurons and cerebral cortex. <p>
FIG. 2, Quantification of the area under the curve (AUC) (Y axis) of the new 48 KDa LRPI fragment analysed in a patient with MDD identified by LC-MS/MS analysis. This fragment LRP1 48 KDa decreases its concentration in the serum of patients with MDD. C (Control), D (Depression).